Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 35 entries
Sorted by: Best Match Show Resources per page
Mutation load and an effector T-cell gene signature may distinguish immunologically distinct and clinically relevant lymphoma subsets.

Blood advances

Bolen CR, McCord R, Huet S, Frampton GM, Bourgon R, Jardin F, Dartigues P, Punnoose EA, Szafer-Glusman E, Xerri L, Sujobert P, Salles G, Venstrom JM.
PMID: 29296835
Blood Adv. 2017 Sep 27;1(22):1884-1890. doi: 10.1182/bloodadvances.2016000786. eCollection 2017 Oct 10.

Identifying follicular lymphoma (FL) patients with preexisting antitumor immunity will inform precision medicine strategies for novel cancer immunotherapies. Using clinical and genomic data from 249 FL patients, we determined the clinical impact of mutation load and an effector T-cell...

Cite
Bolen CR, McCord R, Huet S, et al. Mutation load and an effector T-cell gene signature may distinguish immunologically distinct and clinically relevant lymphoma subsets. Blood Adv. 2017;1(22):1884-1890doi: 10.1182/bloodadvances.2016000786.
Bolen, C. R., McCord, R., Huet, S., Frampton, G. M., Bourgon, R., Jardin, F., Dartigues, P., Punnoose, E. A., Szafer-Glusman, E., Xerri, L., Sujobert, P., Salles, G., & Venstrom, J. M. (2017). Mutation load and an effector T-cell gene signature may distinguish immunologically distinct and clinically relevant lymphoma subsets. Blood advances, 1(22), 1884-1890. https://doi.org/10.1182/bloodadvances.2016000786
Bolen, Christopher R, et al. "Mutation load and an effector T-cell gene signature may distinguish immunologically distinct and clinically relevant lymphoma subsets." Blood advances vol. 1,22 (2017): 1884-1890. doi: https://doi.org/10.1182/bloodadvances.2016000786
Bolen CR, McCord R, Huet S, Frampton GM, Bourgon R, Jardin F, Dartigues P, Punnoose EA, Szafer-Glusman E, Xerri L, Sujobert P, Salles G, Venstrom JM. Mutation load and an effector T-cell gene signature may distinguish immunologically distinct and clinically relevant lymphoma subsets. Blood Adv. 2017 Sep 27;1(22):1884-1890. doi: 10.1182/bloodadvances.2016000786. eCollection 2017 Oct 10. PMID: 29296835; PMCID: PMC5728140.
Copy Download .nbib Format: NLM
[No title available]

Human gene therapy

Rajawat YS, Humbert O, Cook SM, Radtke S, Pande D, Enstrom M, Wohlfahrt ME, Kiem HP.
PMID: 32741228
Hum Gene Ther. 2021 Jan;32(1):113-127. doi: 10.1089/hum.2020.127. Epub 2020 Sep 23.

Hematopoietic stem and progenitor cell (HSPC)-based

Cite
Rajawat YS, Humbert O, Cook SM, et al. . Hum Gene Ther. 2020;32(1):113-127doi: 10.1089/hum.2020.127.
Rajawat, Y. S., Humbert, O., Cook, S. M., Radtke, S., Pande, D., Enstrom, M., Wohlfahrt, M. E., & Kiem, H. P. (2021). . Human gene therapy, 32(1), 113-127. https://doi.org/10.1089/hum.2020.127
Rajawat, Yogendra S, et al. "." Human gene therapy vol. 32,1 (2021): 113-127. doi: https://doi.org/10.1089/hum.2020.127
Rajawat YS, Humbert O, Cook SM, Radtke S, Pande D, Enstrom M, Wohlfahrt ME, Kiem HP. . Hum Gene Ther. 2021 Jan;32(1):113-127. doi: 10.1089/hum.2020.127. Epub 2020 Sep 23. PMID: 32741228; PMCID: PMC8665819.
Copy Download .nbib Format: NLM
Recurrent urothelial carcinoma-like FGFR3 genomic alterations in malignant Brenner tumors of the ovary.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Lin DI, Killian JK, Venstrom JM, Ramkissoon SH, Ross JS, Elvin JA.
PMID: 33077920
Mod Pathol. 2021 May;34(5):983-993. doi: 10.1038/s41379-020-00699-1. Epub 2020 Oct 19.

Malignant Brenner tumor is a rare primary ovarian carcinoma subtype that may present diagnostic and therapeutic conundrums. Here, we characterize the genomics of 11 malignant Brenner tumors, which represented 0.1% of 14,153 clinically advanced ovarian carcinomas submitted for genomic...

Cite
Lin DI, Killian JK, Venstrom JM, et al. Recurrent urothelial carcinoma-like FGFR3 genomic alterations in malignant Brenner tumors of the ovary. Mod Pathol. 2020;34(5):983-993doi: 10.1038/s41379-020-00699-1.
Lin, D. I., Killian, J. K., Venstrom, J. M., Ramkissoon, S. H., Ross, J. S., & Elvin, J. A. (2021). Recurrent urothelial carcinoma-like FGFR3 genomic alterations in malignant Brenner tumors of the ovary. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 34(5), 983-993. https://doi.org/10.1038/s41379-020-00699-1
Lin, Douglas I, et al. "Recurrent urothelial carcinoma-like FGFR3 genomic alterations in malignant Brenner tumors of the ovary." Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc vol. 34,5 (2021): 983-993. doi: https://doi.org/10.1038/s41379-020-00699-1
Lin DI, Killian JK, Venstrom JM, Ramkissoon SH, Ross JS, Elvin JA. Recurrent urothelial carcinoma-like FGFR3 genomic alterations in malignant Brenner tumors of the ovary. Mod Pathol. 2021 May;34(5):983-993. doi: 10.1038/s41379-020-00699-1. Epub 2020 Oct 19. PMID: 33077920.
Copy Download .nbib Format: NLM
Discovery of Potent and Selective Antibody-Drug Conjugates with Eg5 Inhibitors through Linker and Payload Optimization.

ACS medicinal chemistry letters

Karpov AS, Nieto-Oberhuber CM, Abrams T, Beng-Louka E, Blanco E, Chamoin S, Chene P, Dacquignies I, Daniel D, Dillon MP, Doumampouom-Metoul L, Drosos N, Fedoseev P, Furegati M, Granda B, Grotzfeld RM, Hess Clark S, Joly E, Jones D, Lacaud-Baumlin M, Lagasse-Guerro S, Lorenzana EG, Mallet W, Martyniuk P, Marzinzik AL, Mesrouze Y, Nocito S, Oei Y, Perruccio F, Piizzi G, Richard E, Rudewicz PJ, Schindler P, Velay M, Venstrom K, Wang P, Zurini M, Lafrance M.
PMID: 31857845
ACS Med Chem Lett. 2019 Dec 03;10(12):1674-1679. doi: 10.1021/acsmedchemlett.9b00468. eCollection 2019 Dec 12.

Targeted antimitotic agents are a promising class of anticancer therapies. Herein, we describe the development of a potent and selective antimitotic Eg5 inhibitor based antibody-drug conjugate (ADC). Preliminary studies were performed using proprietary Eg5 inhibitors which were conjugated onto...

Cite
Karpov AS, Nieto-Oberhuber CM, Abrams T, et al. Discovery of Potent and Selective Antibody-Drug Conjugates with Eg5 Inhibitors through Linker and Payload Optimization. ACS Med Chem Lett. 2019;10(12):1674-1679doi: 10.1021/acsmedchemlett.9b00468.
Karpov, A. S., Nieto-Oberhuber, C. M., Abrams, T., Beng-Louka, E., Blanco, E., Chamoin, S., Chene, P., Dacquignies, I., Daniel, D., Dillon, M. P., Doumampouom-Metoul, L., Drosos, N., Fedoseev, P., Furegati, M., Granda, B., Grotzfeld, R. M., Hess Clark, S., Joly, E., Jones, D., Lacaud-Baumlin, M., Lagasse-Guerro, S., Lorenzana, E. G., Mallet, W., Martyniuk, P., Marzinzik, A. L., Mesrouze, Y., Nocito, S., Oei, Y., Perruccio, F., Piizzi, G., Richard, E., Rudewicz, P. J., Schindler, P., Velay, M., Venstrom, K., Wang, P., Zurini, M., & Lafrance, M. (2019). Discovery of Potent and Selective Antibody-Drug Conjugates with Eg5 Inhibitors through Linker and Payload Optimization. ACS medicinal chemistry letters, 10(12), 1674-1679. https://doi.org/10.1021/acsmedchemlett.9b00468
Karpov, Alexei S, et al. "Discovery of Potent and Selective Antibody-Drug Conjugates with Eg5 Inhibitors through Linker and Payload Optimization." ACS medicinal chemistry letters vol. 10,12 (2019): 1674-1679. doi: https://doi.org/10.1021/acsmedchemlett.9b00468
Karpov AS, Nieto-Oberhuber CM, Abrams T, Beng-Louka E, Blanco E, Chamoin S, Chene P, Dacquignies I, Daniel D, Dillon MP, Doumampouom-Metoul L, Drosos N, Fedoseev P, Furegati M, Granda B, Grotzfeld RM, Hess Clark S, Joly E, Jones D, Lacaud-Baumlin M, Lagasse-Guerro S, Lorenzana EG, Mallet W, Martyniuk P, Marzinzik AL, Mesrouze Y, Nocito S, Oei Y, Perruccio F, Piizzi G, Richard E, Rudewicz PJ, Schindler P, Velay M, Venstrom K, Wang P, Zurini M, Lafrance M. Discovery of Potent and Selective Antibody-Drug Conjugates with Eg5 Inhibitors through Linker and Payload Optimization. ACS Med Chem Lett. 2019 Dec 03;10(12):1674-1679. doi: 10.1021/acsmedchemlett.9b00468. eCollection 2019 Dec 12. PMID: 31857845; PMCID: PMC6912867.
Copy Download .nbib Format: NLM
Fine Particulate Matter and Total Mortality in Cancer Prevention Study Cohort Reanalysis.

Dose-response : a publication of International Hormesis Society

Enstrom JE.
PMID: 28473741
Dose Response. 2017 Mar 28;15(1):1559325817693345. doi: 10.1177/1559325817693345. eCollection 2017.

BACKGROUND: In 1997 the US Environmental Protection Agency (EPA) established the National Ambient Air Quality Standard (NAAQS) for fine particulate matter (PMMETHODS: The original CPS II questionnaire data, including 1982 to 1988 mortality follow-up, were analyzed using Cox proportional...

Cite
Enstrom JE. Fine Particulate Matter and Total Mortality in Cancer Prevention Study Cohort Reanalysis. Dose Response. 2017;15(1):1559325817693345doi: 10.1177/1559325817693345.
Enstrom, J. E. (2017). Fine Particulate Matter and Total Mortality in Cancer Prevention Study Cohort Reanalysis. Dose-response : a publication of International Hormesis Society, 15(1), 1559325817693345. https://doi.org/10.1177/1559325817693345
Enstrom, James E. "Fine Particulate Matter and Total Mortality in Cancer Prevention Study Cohort Reanalysis." Dose-response : a publication of International Hormesis Society vol. 15,1 (2017): 1559325817693345. doi: https://doi.org/10.1177/1559325817693345
Enstrom JE. Fine Particulate Matter and Total Mortality in Cancer Prevention Study Cohort Reanalysis. Dose Response. 2017 Mar 28;15(1):1559325817693345. doi: 10.1177/1559325817693345. eCollection 2017. PMID: 28473741; PMCID: PMC5407529.
Copy Download .nbib Format: NLM
Real-world association of HER2/.

Future oncology (London, England)

Stein SM, Snider J, Ali SM, Miksad RA, Alexander BM, Castellanos E, Schrock AB, Madison R, Swaminathan A, Venstrom JM, McCusker M.
PMID: 34463133
Future Oncol. 2021 Nov;17(31):4101-4114. doi: 10.2217/fon-2021-0203. Epub 2021 Aug 31.

No abstract available.

Cite
Stein SM, Snider J, Ali SM, et al. Real-world association of HER2/. Future Oncol. 2021;17(31):4101-4114doi: 10.2217/fon-2021-0203.
Stein, S. M., Snider, J., Ali, S. M., Miksad, R. A., Alexander, B. M., Castellanos, E., Schrock, A. B., Madison, R., Swaminathan, A., Venstrom, J. M., & McCusker, M. (2021). Real-world association of HER2/. Future oncology (London, England), 17(31), 4101-4114. https://doi.org/10.2217/fon-2021-0203
Stein, Stacey M, et al. "Real-world association of HER2/." Future oncology (London, England) vol. 17,31 (2021): 4101-4114. doi: https://doi.org/10.2217/fon-2021-0203
Stein SM, Snider J, Ali SM, Miksad RA, Alexander BM, Castellanos E, Schrock AB, Madison R, Swaminathan A, Venstrom JM, McCusker M. Real-world association of HER2/. Future Oncol. 2021 Nov;17(31):4101-4114. doi: 10.2217/fon-2021-0203. Epub 2021 Aug 31. PMID: 34463133.
Copy Download .nbib Format: NLM
Characterization of Non-Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment Patterns.

JCO precision oncology

Lee JK, Madison R, Classon A, Gjoerup O, Rosenzweig M, Frampton GM, Alexander BM, Oxnard GR, Venstrom JM, Awad MM, Schrock AB.
PMID: 34476332
JCO Precis Oncol. 2021 Aug 25;5. doi: 10.1200/PO.21.00122. eCollection 2021.

METHODS: Hybrid capture-based comprehensive genomic profiling (CGP) was performed on samples from 69,219 patients with NSCLC. For treatment patterns and outcomes analysis, patients with advanced RESULTS: A total of 1,592 patients with NSCLC (2.3%) were identified with 1,599 CONCLUSION:...

Cite
Lee JK, Madison R, Classon A, et al. Characterization of Non-Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment Patterns. JCO Precis Oncol. 2021;5doi: 10.1200/PO.21.00122.
Lee, J. K., Madison, R., Classon, A., Gjoerup, O., Rosenzweig, M., Frampton, G. M., Alexander, B. M., Oxnard, G. R., Venstrom, J. M., Awad, M. M., & Schrock, A. B. (2021). Characterization of Non-Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment Patterns. JCO precision oncology, 5. https://doi.org/10.1200/PO.21.00122
Lee, Jessica K, et al. "Characterization of Non-Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment Patterns." JCO precision oncology vol. 5 (2021). doi: https://doi.org/10.1200/PO.21.00122
Lee JK, Madison R, Classon A, Gjoerup O, Rosenzweig M, Frampton GM, Alexander BM, Oxnard GR, Venstrom JM, Awad MM, Schrock AB. Characterization of Non-Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment Patterns. JCO Precis Oncol. 2021 Aug 25;5. doi: 10.1200/PO.21.00122. eCollection 2021. PMID: 34476332; PMCID: PMC8407654.
Copy Download .nbib Format: NLM
Predictive Genomic Biomarkers of Hormonal Therapy Versus Chemotherapy Benefit in Metastatic Castration-resistant Prostate Cancer.

European urology

Graf RP, Fisher V, Mateo J, Gjoerup OV, Madison RW, Raskina K, Tukachinsky H, Creeden J, Cunningham R, Huang RSP, Mata DA, Ross JS, Oxnard GR, Venstrom JM, Zurita AJ.
PMID: 34716049
Eur Urol. 2022 Jan;81(1):37-47. doi: 10.1016/j.eururo.2021.09.030. Epub 2021 Oct 26.

BACKGROUND: Biomarkers predicting second-generation novel hormonal therapy (NHT) benefit relative to taxanes are critical for optimized treatment decisions for metastatic castration-resistant prostate cancer (mCRPC) patients. These associations have not been reported simultaneously for common mCRPC genomic biomarkers.OBJECTIVE: To evaluate...

Cite
Graf RP, Fisher V, Mateo J, et al. Predictive Genomic Biomarkers of Hormonal Therapy Versus Chemotherapy Benefit in Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2021;81(1):37-47doi: 10.1016/j.eururo.2021.09.030.
Graf, R. P., Fisher, V., Mateo, J., Gjoerup, O. V., Madison, R. W., Raskina, K., Tukachinsky, H., Creeden, J., Cunningham, R., Huang, R. S. P., Mata, D. A., Ross, J. S., Oxnard, G. R., Venstrom, J. M., & Zurita, A. J. (2022). Predictive Genomic Biomarkers of Hormonal Therapy Versus Chemotherapy Benefit in Metastatic Castration-resistant Prostate Cancer. European urology, 81(1), 37-47. https://doi.org/10.1016/j.eururo.2021.09.030
Graf, Ryon P, et al. "Predictive Genomic Biomarkers of Hormonal Therapy Versus Chemotherapy Benefit in Metastatic Castration-resistant Prostate Cancer." European urology vol. 81,1 (2022): 37-47. doi: https://doi.org/10.1016/j.eururo.2021.09.030
Graf RP, Fisher V, Mateo J, Gjoerup OV, Madison RW, Raskina K, Tukachinsky H, Creeden J, Cunningham R, Huang RSP, Mata DA, Ross JS, Oxnard GR, Venstrom JM, Zurita AJ. Predictive Genomic Biomarkers of Hormonal Therapy Versus Chemotherapy Benefit in Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2022 Jan;81(1):37-47. doi: 10.1016/j.eururo.2021.09.030. Epub 2021 Oct 26. PMID: 34716049.
Copy Download .nbib Format: NLM
Confronting barriers to human-robot cooperation: balancing efficiency and risk in machine behavior.

iScience

Whiting T, Gautam A, Tye J, Simmons M, Henstrom J, Oudah M, Crandall JW.
PMID: 33458615
iScience. 2020 Dec 17;24(1):101963. doi: 10.1016/j.isci.2020.101963. eCollection 2021 Jan 22.

Many technical and psychological challenges make it difficult to design machines that effectively cooperate with people. To better understand these challenges, we conducted a series of studies investigating human-human, robot-robot, and human-robot cooperation in a strategically rich resource-sharing scenario,...

Cite
Whiting T, Gautam A, Tye J, et al. Confronting barriers to human-robot cooperation: balancing efficiency and risk in machine behavior. iScience. 2020;24(1):101963doi: 10.1016/j.isci.2020.101963.
Whiting, T., Gautam, A., Tye, J., Simmons, M., Henstrom, J., Oudah, M., & Crandall, J. W. (2021). Confronting barriers to human-robot cooperation: balancing efficiency and risk in machine behavior. iScience, 24(1), 101963. https://doi.org/10.1016/j.isci.2020.101963
Whiting, Tim, et al. "Confronting barriers to human-robot cooperation: balancing efficiency and risk in machine behavior." iScience vol. 24,1 (2021): 101963. doi: https://doi.org/10.1016/j.isci.2020.101963
Whiting T, Gautam A, Tye J, Simmons M, Henstrom J, Oudah M, Crandall JW. Confronting barriers to human-robot cooperation: balancing efficiency and risk in machine behavior. iScience. 2020 Dec 17;24(1):101963. doi: 10.1016/j.isci.2020.101963. eCollection 2021 Jan 22. PMID: 33458615; PMCID: PMC7797565.
Copy Download .nbib Format: NLM
[No title available]

Human gene therapy

Rajawat YS, Humbert O, Cook SM, Radtke S, Pande D, Enstrom M, Wohlfahrt ME, Kiem HP.
PMID: 32741228
Hum Gene Ther. 2021 Jan;32(1):113-127. doi: 10.1089/hum.2020.127. Epub 2020 Sep 23.

Hematopoietic stem and progenitor cell (HSPC)-based

Cite
Rajawat YS, Humbert O, Cook SM, et al. . Hum Gene Ther. 2020;32(1):113-127doi: 10.1089/hum.2020.127.
Rajawat, Y. S., Humbert, O., Cook, S. M., Radtke, S., Pande, D., Enstrom, M., Wohlfahrt, M. E., & Kiem, H. P. (2021). . Human gene therapy, 32(1), 113-127. https://doi.org/10.1089/hum.2020.127
Rajawat, Yogendra S, et al. "." Human gene therapy vol. 32,1 (2021): 113-127. doi: https://doi.org/10.1089/hum.2020.127
Rajawat YS, Humbert O, Cook SM, Radtke S, Pande D, Enstrom M, Wohlfahrt ME, Kiem HP. . Hum Gene Ther. 2021 Jan;32(1):113-127. doi: 10.1089/hum.2020.127. Epub 2020 Sep 23. PMID: 32741228; PMCID: PMC8665819.
Copy Download .nbib Format: NLM
Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms.

Clinical cancer research : an official journal of the American Association for Cancer Research

Tukachinsky H, Madison RW, Chung JH, Gjoerup OV, Severson EA, Dennis L, Fendler BJ, Morley S, Zhong L, Graf RP, Ross JS, Alexander BM, Abida W, Chowdhury S, Ryan CJ, Fizazi K, Golsorkhi T, Watkins SP, Simmons A, Loehr A, Venstrom JM, Oxnard GR.
PMID: 33558422
Clin Cancer Res. 2021 Jun 01;27(11):3094-3105. doi: 10.1158/1078-0432.CCR-20-4805. Epub 2021 Feb 08.

PURPOSE: Comprehensive genomic profiling (CGP) is of increasing value for patients with metastatic castration-resistant prostate cancer (mCRPC). mCRPC tends to metastasize to bone, making tissue biopsies challenging to obtain. We hypothesized CGP of cell-free circulating tumor DNA (ctDNA) could...

Cite
Tukachinsky H, Madison RW, Chung JH, et al. Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms. Clin Cancer Res. 2021;27(11):3094-3105doi: 10.1158/1078-0432.CCR-20-4805.
Tukachinsky, H., Madison, R. W., Chung, J. H., Gjoerup, O. V., Severson, E. A., Dennis, L., Fendler, B. J., Morley, S., Zhong, L., Graf, R. P., Ross, J. S., Alexander, B. M., Abida, W., Chowdhury, S., Ryan, C. J., Fizazi, K., Golsorkhi, T., Watkins, S. P., Simmons, A., Loehr, A., Venstrom, J. M., & Oxnard, G. R. (2021). Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(11), 3094-3105. https://doi.org/10.1158/1078-0432.CCR-20-4805
Tukachinsky, Hanna, et al. "Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,11 (2021): 3094-3105. doi: https://doi.org/10.1158/1078-0432.CCR-20-4805
Tukachinsky H, Madison RW, Chung JH, Gjoerup OV, Severson EA, Dennis L, Fendler BJ, Morley S, Zhong L, Graf RP, Ross JS, Alexander BM, Abida W, Chowdhury S, Ryan CJ, Fizazi K, Golsorkhi T, Watkins SP, Simmons A, Loehr A, Venstrom JM, Oxnard GR. Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms. Clin Cancer Res. 2021 Jun 01;27(11):3094-3105. doi: 10.1158/1078-0432.CCR-20-4805. Epub 2021 Feb 08. PMID: 33558422.
Copy Download .nbib Format: NLM
Comprehensive genomic profiling of histologic subtypes of urethral carcinomas.

Urologic oncology

Jacob J, Necchi A, Grivas P, Hughes M, Sanford T, Mollapour M, Shapiro O, Talal A, Sokol E, Vergilio JA, Killian J, Lin D, Williams E, Tse J, Ramkissoon S, Severson E, Hemmerich A, Ferguson N, Edgerly C, Duncan D, Huang R, Chung J, Madison R, Alexander B, Venstrom J, Reddy P, McGregor K, Elvin J, Schrock A, Danziger N, Pavlick D, Ross J, Bratslavsky G.
PMID: 34215504
Urol Oncol. 2021 Oct;39(10):731.e1-731.e15. doi: 10.1016/j.urolonc.2020.12.021. Epub 2021 Jun 30.

BACKGROUND: Carcinoma of the urethra (UrthCa) is an uncommon Genitourinary (GU) malignancy that can progress to advanced metastatic disease.METHODS: One hundred twenty-seven metastatic UrthCa underwent hybrid capture-based comprehensive genomic profiling to evaluate all classes of genomic alterations (GA). Tumor...

Cite
Jacob J, Necchi A, Grivas P, et al. Comprehensive genomic profiling of histologic subtypes of urethral carcinomas. Urol Oncol. 2021;39(10):731.e1-731.e15doi: 10.1016/j.urolonc.2020.12.021.
Jacob, J., Necchi, A., Grivas, P., Hughes, M., Sanford, T., Mollapour, M., Shapiro, O., Talal, A., Sokol, E., Vergilio, J. A., Killian, J., Lin, D., Williams, E., Tse, J., Ramkissoon, S., Severson, E., Hemmerich, A., Ferguson, N., Edgerly, C., Duncan, D., Huang, R., Chung, J., Madison, R., Alexander, B., Venstrom, J., Reddy, P., McGregor, K., Elvin, J., Schrock, A., Danziger, N., Pavlick, D., Ross, J., & Bratslavsky, G. (2021). Comprehensive genomic profiling of histologic subtypes of urethral carcinomas. Urologic oncology, 39(10), 731.e1-731.e15. https://doi.org/10.1016/j.urolonc.2020.12.021
Jacob, Joseph, et al. "Comprehensive genomic profiling of histologic subtypes of urethral carcinomas." Urologic oncology vol. 39,10 (2021): 731.e1-731.e15. doi: https://doi.org/10.1016/j.urolonc.2020.12.021
Jacob J, Necchi A, Grivas P, Hughes M, Sanford T, Mollapour M, Shapiro O, Talal A, Sokol E, Vergilio JA, Killian J, Lin D, Williams E, Tse J, Ramkissoon S, Severson E, Hemmerich A, Ferguson N, Edgerly C, Duncan D, Huang R, Chung J, Madison R, Alexander B, Venstrom J, Reddy P, McGregor K, Elvin J, Schrock A, Danziger N, Pavlick D, Ross J, Bratslavsky G. Comprehensive genomic profiling of histologic subtypes of urethral carcinomas. Urol Oncol. 2021 Oct;39(10):731.e1-731.e15. doi: 10.1016/j.urolonc.2020.12.021. Epub 2021 Jun 30. PMID: 34215504.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 35 entries